Information Provided By: 
Fly News Breaks for January 4, 2018
ABT, DXCM
Jan 4, 2018 | 10:56 EDT
Piper Jaffray analyst JP McKim believes Abbott's (ABT) Medicare approval for Libre is "more market-expanding than share-taking" for Dexcom (DXCM), and maintained an Overweight rating on Dexcom shares, seeing the pullback as a buying opportunity for longer-term investors. Dexcom shares are down 8.75% to $53 in late morning trading.
News For DXCM;ABT From the Last 2 Days
ABT
Apr 18, 2024 | 21:44 EDT
ABT
Apr 18, 2024 | 09:14 EDT
RBC Capital lowered the firm's price target on Abbott to $125 from $128 but keeps an Outperform rating on the shares. The analyst states that despite a strong Q1 with 10.8% underlying revenue and double-digit EPS growth, the stock was down 3%, which reflects sentiment on the broader MedTech space, where high expectations require a beat and raise for stocks to be rewarded. RBC maintains however that it sees upside potential for Abbott "as 2024 drivers take hold".
